source
- Spruce Biosciences spins out preclinical endocrinology program into new unit Adrenyx, backed by up to $50 millionSpruce Biosciences announced it is creating a separate subsidiary to house its preclinical endocrinology research. The new company, named Adrenyx Biosciences, will focus on advancing the early-sta…
- Vir hepatitis D drug succeeds in first pivotal studyA program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more potent than a rival drug also in late-stage development.BioPharma Dive · 1d ago↗ source